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 Summary 
 
Alzheimer’s disease (AD) is the most common form of dementia that gradually worsens over 
time and leads to death. AD is characterized by an accumulation of β-amyloid protein (Aβ) in 
the brain. Recently, the 39-kDa receptor-associated protein (RAP) has been implicated in the 
AD pathology. RAP is found mainly in endoplasmic reticulum (ER) and functions as a 
chaperone for the maturation and trafficking of the low density lipoprotein (LDL) receptor 
family. Polymorphisms in the RAP gene have been associated with an increased risk of AD. 
Two studies have shown that down-regulation of RAP expression exacerbates Aβ pathology 
in transgenic mouse models of AD, suggesting that RAP may have an important role in Aβ 
production and clearance. It has been also shown that RAP binds strongly to Aβ, leading to an 
inhibition of Aβ aggregation and neurotoxicity. Furthermore, a recent study has shown that 
the level of RAP expression is significantly decreased in the AD brain compared with healthy 
controls. 
 
This study aimed to identify the region of RAP which binds to Aβ and the effect of RAP 
over-expression and treatment on APP metabolism and Aβ production. The possibility that Aβ 
can bind to RAP in the human CSF was also examined. To determine the Aβ-binding region 
on RAP, an in-vitro assay was established and validated to study Aβ-self association, based 
on the binding of biotin labelled Aβ42 to synthetic Aβ42 seeded in the wells of microplates. 
The Aβ-binding region on RAP was identified by measuring Aβ-self association in the 
presence of different RAP fragments. The results indicated that the Aβ-binding site was 
located between amino acid residues 206 and 216 of the RAP sequence in loop region 
between domains D2 and D3. To examine the effect of RAP on APP metabolism, two 
strategies were used. The first strategy involved over-expression of RAP in sweAPP-CHO 
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and sweAPP-SH-SY5Y cells, after which the effect of RAP on APP processing and Aβ 
production was analysed. As a second strategy, the effect of RAP on APP metabolism was 
examined in primary cortical neurons derived from Tg2576 transgenic mice. The results 
showed that over-expression or treatment of RAP had no significant effect on the level of 
total APP. However, the levels of sAPPβ, C99 and Aβ were decreased and the production of 
C83 was significantly increased in RAP-transfected cells. The results suggest that RAP could 
decrease Aβ production by decreasing β-cleavage. Therefore, a decreased level of RAP in the 
brain could contribute to the pathogenesis of AD. Attempts to determine if Aβ can bind with 
RAP in the human CSF were not successful; the preliminary results, however, suggested that 
Clusterin/CLU is the main Aβ-binding protein in the human CSF. Taken together, these data 
suggest that RAP is a protective factor against Alzheimer’s disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
